Recursion Pharmaceuticals (NASDAQ:RXRX) Stock: Insider Blake Borgeson Sells 40,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 40,000 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $3.88, for a total value of $155,200.00. Following the transaction, the director directly owned 6,068,287 shares in the company, valued at approximately $23,544,953.56. The trade was a 0.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, October 6th, Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $4.84, for a total value of $242,000.00.
• On Tuesday, September 1st, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.34, for a total value of $100,200.00.

Recursion Pharmaceuticals Trading Up 5.4%

NASDAQ RXRX traded up $0.20 during trading on Wednesday, hitting $3.88. The stock had a trading volume of 20,553,455 shares, compared to its average volume of 19,663,393. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $2.08 billion, a PE ratio of -4.31 and a beta of 1.15. The firm has a 50 day moving average price of $3.76 and a 200 day moving average price of $3.53. Recursion Pharmaceuticals, Inc. has a twelve month low of $2.77 and a twelve month high of $5.24.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.22). Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 46.47%. The business had revenue of $18.55 million for the quarter, compared to analysts’ expectations of $14.81 million. During the same quarter in the prior year, the company earned ($0.36) earnings per share. As a group, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.93 earnings per share for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several large investors have recently bought and sold shares of the business. MCF Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $27,000. Park Avenue Securities LLC purchased a new position in shares of Recursion Pharmaceuticals in the 3rd quarter valued at $47,000. Fund Advisors of America Inc FL acquired a new stake in Recursion Pharmaceuticals during the 2nd quarter worth $45,000. Kestra Private Wealth Services LLC acquired a new stake in Recursion Pharmaceuticals during the 3rd quarter worth $58,000. Finally, Sequoia Financial Advisors LLC raised its stake in Recursion Pharmaceuticals by 51.5% during the 1st quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after acquiring an additional 5,156 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on RXRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, October 17th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Finally, Morgan Stanley set a $5.90 price target on shares of Recursion Pharmaceuticals in a research note on Friday, October 16th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $8.18.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.